FEATURED ARTICLE

 

Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress? 2018

PR Newswire  2018-04-17 14:31:00

PALO ALTO, Calif., April 17, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The International Liver Congress? 2018, in...

Full Story »

Comments

No Comments
Your name: *
Email:
Comment: *
 
Share
submit to reddit
CheapOair.com